Market Place
Sourcing Support
Jiangsu Hengrui Pharma Receives FDA Warning Letter
16 Jul 2024 //
FDA
Hengrui Pharma`s Generic Bupivacaine liposome Receives Approval in US
02 Jul 2024 //
FDA
FDA hands Chinese drug Mfg Form 483 noting employees destroyed documents
05 Jun 2024 //
ENDPTS
FDA Issues Form 483 to Jiangsu Hengrui Pharmceuticals
04 Jun 2024 //
FDA
FDA rejects Elevar, Hengrui`s PD-1 combo
18 May 2024 //
FIERCE PGARMA
Investors put $400M into biotech licensing obesity drugs from China
17 May 2024 //
BIOPHARMADIVE
Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
17 Oct 2023 //
GLOBENEWSWIRE
Mycovia Announces Partner Jiangsu Hengrui`s Approval of Oteseconazole Capsules
21 Aug 2023 //
PR NEWSWIRE
Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR
10 Apr 2023 //
PRESS RELEASE
Camrelizumab with Rivoceranib vs. Sorafenib, a Joint Program with Elevar
11 Sep 2022 //
PRNEWSWIRE
Camrelizumab in Combo with Rivoceranib Significantly Prolonged Overall Survival
10 Sep 2022 //
PRESS RELEASE
Dalpiciclib in Combo with Letrozole or Anastrozole Significantly Progression
29 Aug 2022 //
PRESS RELEASE
Small Molecules Attract Investors As Two Chinese Biotechs Bag $161m
19 May 2022 //
SCRIP
Chinese pharma giant Hengrui launches new company for globalization play
19 May 2022 //
ENDPTS
Hengrui Pharma Announces Frontline Camrelizumab in Combination with Rivoceranib
13 May 2022 //
PRESS RELEASE
Another Chinese PD-1 cancer med eyes FDA filing in liver cancer
12 May 2022 //
FIERCEPHARMA
Jiangsu Hengrui`s Generic Gadoterate Meglumine Receives Approval in the U.S.
11 Apr 2022 //
FDA
PhII results of vunakizumab in patients with moderate-to-severe plaque psoriasis
10 Feb 2022 //
PRESS RELEASE
First patient dosed in the first-in-human study of a novel ATR inhibitor
10 Jan 2022 //
PRESS RELEASE
NMPA approves AiRuiKang® in combination with fulvestrant
03 Jan 2022 //
PRESS RELEASE
First participant dosed in the first-in-human study of a novel GLP-1/GIP agonist
23 Dec 2021 //
PRESS RELEASE
First patient dosed in a proof-of-concept Phase II study of SHR1459
20 Dec 2021 //
PRESS RELEASE
First patient dosed in pivotal study of Hengrui`s novel EZH2 inhibitor SHR2554
13 Dec 2021 //
PRESS RELEASE
Primary endpoint met in a Ph III study of the anti-PD-L1 antibody Adebrelimab
29 Nov 2021 //
PRESS RELEASE
CStone, Jiangsu Hengrui partner and sign agreement on anti-CTLA-4 MAb CS1002
20 Nov 2021 //
PRNEWSWIRE
Ph III interim data of dalpiciclib in combination with fulvestrant in HR+/HER2
18 Nov 2021 //
PRESS RELEASE
Enrollment completed for PhI study of SHR-1707, an anti-?-amyloid monol antibody
15 Nov 2021 //
PRESS RELEASE
NMPA IND clearance to initiate a Phase Ib/III study of fuzuloparib
13 Oct 2021 //
PRESS RELEASE
First patient dosed in the U.S. in a global Phase III study of fuzuloparib
12 Oct 2021 //
PRESS RELEASE
The USFDA clearance to initiate a Phase I/IIa study for a novel Claudin 18.2 ADC
30 Sep 2021 //
PRESS RELEASE
NMPA IND clearance to initiate a Phase II study of SHR7280, an oral GnRH
29 Sep 2021 //
PRESS RELEASE
NDA filing accepted by NMPA for pyrotinib neoadjuvant treatment of early-stage
23 Sep 2021 //
PRESS RELEASE
First patient dosed in Korea in a global Phase I study for SHR-A1811, a HER2 ADC
16 Sep 2021 //
PRESS RELEASE
NMPA IND clearances to initiate a Ph II/III study & a Ph III study of SHR-1701
15 Sep 2021 //
PRESS RELEASE
NMPA Breakthrough Therapy Designation granted for SHR3680
07 Sep 2021 //
PRESS RELEASE
Dosing completed the first cohort of the first-in-human (FIH) study for SHR-1906
31 Aug 2021 //
PRESS RELEASE
BeyondSpring nails a $200M China deal in wake of a pivotal success
27 Aug 2021 //
ENDPTS
NMPA IND clearance to initiate PhII study vunakizumab active psoriatic arthritis
25 Aug 2021 //
PRESS RELEASE
Positive interim analysis announced for SHR3680 in a Phase III
16 Jul 2021 //
PRESS RELEASE
NMPA approves a new indication of camrelizumab: combined with chemotherapy
17 Jun 2021 //
PRESS RELEASE
Hengrui presented 64 studies at ASCO 2021, including 5 oral presentations
15 Jun 2021 //
PRESS RELEASE
Hengrui Pharma ranked the 38th out of the top 50 in the PharmExec 2021
11 Jun 2021 //
PRESS RELEASE
Jiangsu Hengrui’s Generic Carmustine Receives Approval In US
17 Mar 2021 //
FDA
Thermo Fisher inks CDx agreement with Hengrui Therapeutics
23 Aug 2020 //
BIOSPECTRUM
Thermo Fisher Scientific inks companion diagnostic agreement with Hengrui
17 Aug 2020 //
PHARMABIZ
BeiGene hits back at short seller`s accusations of 60% sales inflation
10 Sep 2019 //
FIERCE PHARMA
Jiangsu Hengrui’s Generic Daptomycin Receives Approval In US
27 Aug 2019 //
FDA
Eli Lilly, BMS among 77 drugmakers targeted in Chinese financial probe
04 Jun 2019 //
FIERCE PHARMA
Fast moving Chinese regulators wave third homegrown PD-1 to market
01 Jun 2019 //
ENDPTS
What`s BeiGene`s plan for Celgene-partnered PD-1?
31 May 2019 //
FIERCE PHARMA
China`s Generic Drugmakers Struggle to Survive After $46 Billion Plunge
02 Jan 2019 //
CAIXIN NEWS CN
Jiangsu Hengrui’s Generic Fondaparinux Sodium Receives Approval In US
18 May 2018 //
FDA
Jiangsu Hengrui Med Generic Thiotepa Receives Approval In US
07 May 2018 //
FDA
PrecedexTM (Dexmedetomidine Hydrochloride): Hospira v. Jiangsu Hengrui Medicine
01 Feb 2018 //
PATENT LITIGATION
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
06 Jan 2018 //
FIERCE PHARMA
Jiangsu Hengrui’s Generic Gabapentin Receives Approval In US
27 Oct 2017 //
FDA
Jiangsu Hengrui Med’s Generic Cisatracurium Besylate Receives Approval In US
01 Sep 2017 //
FDA
